Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging

Silvia Giordano, Massimo Zucchetti, Alessandra Agnese Decio, Marta Cesca, I. Fuso Nerini, Marika Maiezza, Mariella Ferrari, Simonetta Andrea Licandro, Roberta Frapolli, Raffaella Giavazzi, Maurizio D'Incalci, Enrico Davoli, Lavinia Morosi

Research output: Contribution to journalArticlepeer-review


The penetration of anticancer drugs in solid tumors is important to ensure the therapeutic effect, so methods are needed to understand drug distribution in different parts of the tumor. Mass spectrometry imaging (MSI) has great potential in this field to visualize drug distribution in organs and tumor tissues with good spatial resolution and superior specificity. We present an accurate and reproducible imaging method to investigate the variation of drug distribution in different parts of solid tumors. The method was applied to study the distribution of paclitaxel in three ovarian cancer models with different histopathological characteristics and in colon cancer (HCT116), breast cancer (MDA-MB-231) and malignant pleural mesothelioma (MPM487). The heterogeneous drug penetration in the tumors is evident from the MALDI imaging results and from the images analysis. The differences between the various models do not always relate to significant changes in drug content in tumor homogenate examined by classical HPLC analysis. The specificity of the method clarifies the heterogeneity of the drug distribution that is analyzed from a quantitative point of view too, highlighting how marked are the variations of paclitaxel amounts in different part of solid tumors.

Original languageEnglish
Pages (from-to)39284
JournalScientific Reports
Publication statusPublished - Dec 21 2016

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging'. Together they form a unique fingerprint.

Cite this